TQBWX 220
Alternative Names: TQBWX220Latest Information Update: 28 May 2022
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in China (PO)
- 21 Apr 2018 Preclinical trials in Colorectal cancer in China (PO), prior to April 2018
- 21 Apr 2018 Pharmacodynamics data from preclinical trials in Colorectal cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)